4007-79-8

Basic information

• Product Name: 5,5-DiMethylpiperidin-2-one
• Synonyms: 5,5-DiMethylpiperidin-2-one
• CAS NO: 4007-79-8
• Molecular Formula: C₇H₁₃NO
• Molecular Weight: 127.18422
• Mol File: 4007-79-8.mol
• Article Data: 5

Chemical Properties

• Melting Point: 120-124 °C
• Boiling Point: 247.2±9.0 °C(Predicted)
• Appearance: /
• Density: 0.925±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 16.68±0.40(Predicted)
• CAS DataBase Reference: 5,5-DiMethylpiperidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5,5-DiMethylpiperidin-2-one(4007-79-8)
• EPA Substance Registry System: 5,5-DiMethylpiperidin-2-one(4007-79-8)

Safety Data

• Hazardous Substances Data: 4007-79-8(Hazardous Substances Data)

Usage

General Description

5,5-Dimethylpiperidin-2-one is a chemical compound with the molecular formula C8H15NO. It is a cyclic amide that is commonly used as a precursor in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is a colorless liquid with a faint amine-like odor and is soluble in water, alcohols, and ethers. 5,5-Dimethylpiperidin-2-one is also used as a stabilizer in polymers and as an intermediate in the production of UV absorbers and antioxidants. It is important to handle this compound with care as it may cause skin and eye irritation, and prolonged exposure should be avoided to prevent potential health risks.

Upstream product

• 20500-49-6 3,3-dimethylcyclopentanone 
• 946082-44-6 ethyl 4-cyano-4-methylpentanoate 

Downstream Products

• 483358-28-7 6-ethoxy-3,3-dimethyl-2,3-dihydro-pyridine 
• 179685-59-7 1-Aza-2-methoxy-5,5-dimethyl-1-cyclohexene 

Relevant articles and documents

METABOTROPIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF

Compounds that modulate GluR5 activity and methods of using the same are disclosed.

Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Synthesis and biological evaluation of dihydropyridin-2(1H)-imines and 1,5,6,7-tetrahydro-2H-azepin-2-imines

The process of discovery and biological evaluation of α,β-unsaturated cyclic amidines, as selective inhibitors of inducible nitric oxide synthase (iNOS), is reported. Dihydropyridin-2(1H)-imines and 1,5,6,7-tetrahydro-2H-azepin-2-imines were synthesized a

Cyclic amidine analogs as inhibitors of nitric oxide synthase

Disclosed herein are compounds of Formula I STR1 and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These disease and disorders include hypotension, septic shock, toxic shock syndrom, hemodialysis, IL-2 therapy such as in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn or psoriasis and respiratory conditions such as bronchitis, asthma, and acure respiratory distress (ARDS), myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis. Compounds of Formula I are also usful in the treatment of hypoxia, hyperbaric oxygen convulsions and toxicity, dementia, Sydenham's chorea, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, mulitple sclerosis, Korsakoff's disease, imbecility related to cerebral vessel disorder, ischemic brain edema, sleeping disorders, schizophrenia, depression, PMS, anxiety, drug addiction, pain, migraine, immune complex disease, as immunosupressive agents and for preventing or reversing tolerance to opiates and diazepines.